Cancer cells losing large numbers of chromosomes follow two fundamentally different evolutionary paths with vastly different patient outcomes, challenging the assumption that chromosome loss always signals aggressive disease. This distinction could revolutionize how oncologists assess prognosis and select treatments for thousands of patients annually.
Analysis of over 17,000 cancer genomes across 34 tumor types revealed that hypodiploid cancers—those missing significant chromosomal material—split into unstable and stable categories. Unstable hypodiploid tumors exhibit chaotic genomic behavior with frequent chromosome doubling events, extensive DNA rearrangements, and high mutation rates in the TP53 tumor suppressor gene. These cancers show marked oxygen deprivation and extreme genetic diversity within individual tumors. Conversely, stable hypodiploid cancers, particularly acute lymphoblastic leukemia, kidney chromophobe, and adrenocortical carcinoma, demonstrate predictable chromosome loss patterns with minimal ongoing genomic disruption.
This finding upends conventional wisdom linking chromosome loss to uniformly poor outcomes. The stable subset maintains consistent genetic profiles that appear compatible with controlled growth, while unstable variants drive relentless tumor evolution and treatment resistance. The research team developed a cytogenetic-based method to distinguish masked hypodiploid from hyperdiploid acute lymphoblastic leukemia, potentially preventing misclassification that could lead to inappropriate treatment intensification. The work suggests that genomic stability, rather than chromosome number alone, determines cancer aggressiveness. This paradigm shift may enable more nuanced risk assessment and personalized therapeutic approaches for cancers previously grouped together based solely on chromosome counts.